Nancy A. Grygiel - May 2, 2023 Form 4 Insider Report for AMGEN INC (AMGN)

Role
SVP & CCO
Signature
/s/ Nancy A. Grygiel
Stock symbol
AMGN
Transactions as of
May 2, 2023
Transactions value $
-$14,630
Form type
4
Date filed
5/4/2023, 08:35 PM
Previous filing
May 2, 2023
Next filing
May 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Award $0 +635 +4.63% $0.00 14.3K May 2, 2023 Direct F1
transaction AMGN Common Stock Tax liability -$14.6K -62 -0.43% $235.97 14.3K May 3, 2023 Direct F2, F3
holding AMGN Common Stock 96.6 May 2, 2023 401(k) Plan F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Award $0 +5.38K $0.00 5.38K May 2, 2023 Common Stock 5.38K $235.97 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
F2 These shares include the following RSUs granted under the Company's equity plans: 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3 These shares include 584 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
F5 These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.